Literature DB >> 21983801

Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin.

Natale Daniele Brunetti1, Deodata Montrone, Riccardo Ieva, Antonio Ruggiero, Michele Correale, Luisa De Gennaro, Matteo Di Biase.   

Abstract

We describe the case of a 22-year old woman affected by familial hypercholesterolemia, referred for chest pain and treated with angioplasty of left anterior descending coronary artery. Marked systemic inflammation associated with acute coronary syndrome was reduced by 1-month therapy with high dose atorvastatin.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21983801     DOI： 10.1007/s11239-011-0638-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  16 in total

1.  The effect of selective low-density lipoprotein apheresis on plasma lipoperoxides and antioxidant vitamins in familial hypercholesterolemic patients.

Authors:  R Baricchi; R Pizzala; G Cacciavillani; P Rivasi; A Tomasi
Journal:  Ther Apher       Date:  1998-08

Review 2.  Ezetimibe plus simvastatin cardiovascular outcomes study program.

Authors:  Luis Rodríguez Padial
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-01

3.  Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10.

Authors:  Ingunn Narverud; Thor Ueland; Marit S Nenseter; Kjetil Retterstøl; Vibeke H Telle-Hansen; Bente Halvorsen; Leiv Ose; Pål Aukrust; Kirsten B Holven
Journal:  Atherosclerosis       Date:  2010-11-01       Impact factor: 5.162

4.  Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins.

Authors:  D Hausmann; J A Johnson; K Sudhir; W L Mullen; G Friedrich; P J Fitzgerald; T M Chou; T A Ports; J P Kane; M J Malloy; P G Yock
Journal:  J Am Coll Cardiol       Date:  1996-06       Impact factor: 24.094

5.  Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.

Authors:  P N Hopkins; S Stephenson; L L Wu; W A Riley; Y Xin; S C Hunt
Journal:  Am J Cardiol       Date:  2001-03-01       Impact factor: 2.778

6.  Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES.

Authors:  Kirsten B Holven; Jan K Damås; Arne Yndestad; Torgun Waehre; Thor Ueland; Bente Halvorsen; Lars Heggelund; Wiggo J Sandberg; Anne G Semb; Stig S Frøland; Leiv Ose; Marit S Nenseter; Pål Aukrust
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-27       Impact factor: 8.311

7.  Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

Authors:  G Avellone; V Di Garbo; V Guarnotta; R Scaglione; G Parrinello; L Purpura; D Torres; D Campisi
Journal:  Int Angiol       Date:  2010-12       Impact factor: 2.789

8.  The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study.

Authors:  T Waidner; D Franzen; W Voelker; M Ritter; H Borberg; V Hombach; H W Höpp
Journal:  Clin Investig       Date:  1994-11

Review 9.  Apolipoprotein polymorphisms and familial hypercholesterolemia.

Authors:  George V Z Dedoussis
Journal:  Pharmacogenomics       Date:  2007-09       Impact factor: 2.533

10.  Lipoprotein(a) as a cardiovascular risk factor: current status.

Authors:  Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2010-10-21       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.